Flippers have been conditioned to sell on any news
Post# of 30025
Posted On: 09/03/2014 9:45:37 PM
Re: tyfoiddhana #5490
Flippers have been conditioned to sell on any news, call, conference, tweet or wink as it's worked the majority of the time in the past. It's worth the gamble that there won't be back to back news. Doesn't help when people are posting the partnership is a done deal leading up to the call.
With the number of irons Amarantus has in the fire and with milestones drawing near, any sell off is being met with more new buyers coming in which will result in less volatility moving forward. The days of playing musical shares are dwindling fast. Some folks are going to be left without a seat when the music stops or paying a premium to get back in.
The current SP doesn't even reflect the potential of LymPro, let alone all the other assets. Even more of a reason to spin off assets so the market can recognize the true value of the parts without one overshadowing the rest or adding additional risk to the other assets.
If LymPro is a $3B opportunity down the road, what about Eltoprazine, MANF, PhenoGuard...
Gerald and John know the tremendous value of the assets. What they cannot predict is when the market will realize it. It's only a matter of time.
With the number of irons Amarantus has in the fire and with milestones drawing near, any sell off is being met with more new buyers coming in which will result in less volatility moving forward. The days of playing musical shares are dwindling fast. Some folks are going to be left without a seat when the music stops or paying a premium to get back in.
The current SP doesn't even reflect the potential of LymPro, let alone all the other assets. Even more of a reason to spin off assets so the market can recognize the true value of the parts without one overshadowing the rest or adding additional risk to the other assets.
If LymPro is a $3B opportunity down the road, what about Eltoprazine, MANF, PhenoGuard...
Gerald and John know the tremendous value of the assets. What they cannot predict is when the market will realize it. It's only a matter of time.
Quote:
At $1,000 per test, that creates a potential $3.0 billion opportunity for LymPro once final commercial approval is granted.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼